NCT06879951

Brief Summary

Obesity and periodontitis are chronic inflammatory diseases that share common pathological mechanisms. Asprosin, a novel adipokine discovered in 2016, has not been extensively studied in relation to periodontal tissues. In our study, we investigate the levels of asprosin in both serum and gingival crevicular fluid of patients with obesity and those of normal weight who have periodontitis. Additionally, our research aims to clarify the pathophysiological mechanisms linking periodontitis and obesity by examining local and systemic levels of TNF-α, IL-6, and asprosin, alongside clinical periodontal parameters.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Aug 2023

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 8, 2023

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 10, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 10, 2024

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

March 11, 2025

Completed
6 days until next milestone

First Posted

Study publicly available on registry

March 17, 2025

Completed
Last Updated

March 17, 2025

Status Verified

March 1, 2025

Enrollment Period

1 year

First QC Date

March 11, 2025

Last Update Submit

March 11, 2025

Conditions

Keywords

PeriodontitisObesityAsprosinChronic Inflammatory Diseases

Outcome Measures

Primary Outcomes (1)

  • Biyomarker levels

    All groups' GCF and serum levels of asprosin, TNF-α, and IL-6 levels

    08.10.2023-08.10.2024

Study Arms (4)

Obese individiuals with periodontitis

Other: Participants are not assigned an intervention as part of the study.

Obese individuals with periodontal healthy

Other: Participants are not assigned an intervention as part of the study.

Normal-weight Individuals with Periodontitis

Other: Participants are not assigned an intervention as part of the study.

Normal-weight Individuals with periodontal health

Other: Participants are not assigned an intervention as part of the study.

Interventions

Participants are not assigned an intervention as part of the study.

Normal-weight Individuals with PeriodontitisNormal-weight Individuals with periodontal healthObese individiuals with periodontitisObese individuals with periodontal healthy

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients were recruited from the Periodontology Clinic at Gazi University Faculty of Dentistry between August 2023 and August 2024. All participants who met the inclusion criteria were included in the study. Before their participation, the study's purpose and methods were explained, and written informed consent was obtained.

You may qualify if:

  • Willingness to participate in the study.
  • Weight classification:
  • Obese individuals: Body mass index (BMI) of 30 kg/m² or higher.
  • Normal-weight individuals: BMI between 18.5 and 24.9 kg/m².
  • Periodontal health status:
  • Bleeding on probing: less than 10%.
  • Periodontal pocket depth: less than 3 mm.
  • No sites showing attachment loss or alveolar bone loss on radiographs.
  • For individuals with periodontitis:
  • At least two non-adjacent teeth must show signs of interdental attachment loss.
  • Periodontal pocket depth greater than 3 mm.

You may not qualify if:

  • Individuals who have received periodontal therapy, any oral decontamination treatment, or antibiotics or steroids in the six months prior to the start of the study.
  • Individuals who are pregnant or breastfeeding.
  • Individuals diagnosed with rheumatoid arthritis or lupus erythematosus.
  • Individuals with a medical history of radiation or cancer therapy.
  • Patients with diabetes, defined by:
  • Hemoglobin A1c (HbA1c) level greater than 6.5%.
  • Fasting blood glucose (FBG) greater than 126 mg/dL.
  • An abnormal oral glucose tolerance test (OGTT).
  • Smokers.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Gazi University Faculty of Dentistry

Ankara, 06490, Turkey (Türkiye)

Location

MeSH Terms

Conditions

PeriodontitisObesityArachnodactyly

Condition Hierarchy (Ancestors)

Periodontal DiseasesMouth DiseasesStomatognathic DiseasesOverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsLimb Deformities, CongenitalMusculoskeletal AbnormalitiesMusculoskeletal DiseasesCongenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and Abnormalities

Study Officials

  • Aysen Bodur, Professor

    Gazi University Faculty of Dentistry Department of Periodontology

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Research assistant

Study Record Dates

First Submitted

March 11, 2025

First Posted

March 17, 2025

Study Start

August 8, 2023

Primary Completion

August 10, 2024

Study Completion

August 10, 2024

Last Updated

March 17, 2025

Record last verified: 2025-03

Data Sharing

IPD Sharing
Will not share

Locations